What do systematic reviews say?

GLP‐1 agonists vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 279 participants
  Low

GLP‐1 agonists vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 303 participants
  Low

GLP‐1 agonists vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 303 participants
  Low

Glitazone vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 88 participants
  Very low

Glitazone vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 233 participants
  Very low

Glitazone vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 52 participants
  Very low

Glitazone vs placebo

The review found no eligible studies for this question.

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Glitazone vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 222 participants
  Very low

Glitazone vs placebo

The review found no eligible studies for this question.

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Glitazone vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 70 participants
  Very low

Glitazone vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 63 participants
  Very low

SGLT2 inhibitors vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2788 participants
  Low

SGLT2 inhibitors vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1029 participants
  Low

SGLT2 inhibitors vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 848 participants
  Moderate

SGLT2 inhibitors vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 3086 participants
  Low

SGLT2 inhibitors vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 917 participants
  Very low

DPP‐4 inhibitors vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 867 participants
  Low

Oral or topical or intraperitoneal antibiotics vs placebo/no treatment

Oral or topical or intraperitoneal antibiotics showed no clear difference in peritonitis (number of patients with one or more episodes) compared with placebo/no treatment (low certainty).

• Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.82 [0.57, 1.19]
  5 studies · 395 participants
  Low

Any antifungal intervention for the treatment of oral candidiasis vs placebo/no treatment

Antifungal may leads to lower fungal peritonitis (number of patients with one or more episodes) compared with placebo/no treatment (low certainty).

• Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.28 [0.12, 0.63]
  2 studies · 817 participants
  Low

Oral or topical or intraperitoneal antibiotics vs placebo/no treatment

Oral or topical or intraperitoneal antibiotics showed no clear difference in exit‐site/tunnel infection (number of patients with one or more… compared with placebo/no treatment (low certainty).

• Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients 2017 · Cochrane Headline outcomes only
  RR 0.45 [0.19, 1.04]
  3 studies · 191 participants
  Low